[60] The only concern regarding the use of TKI as first-line therapy of patients with NSCLC harboring EGFR mutations can be the turnaround time of the EGFR mutation test. In clinical practice ...
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
described a family in which multiple members developed NSCLC associated with germline ... are associated with EGFR TKI resistance.
Osimertinib has set the paradigm over the past 5 years for advanced NSCLC with common EGFR mutations ... and MARIPOSA (lazertinib, a third-generation EGFR TKI, plus amivantamab, a bispecific antibody ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
A pooled analysis of sunvozertinib in EGFR TKI-resistant NSCLC showed promising antitumor activity and favorable safety, achieving a 27.5% objective response rate. Data from a pooled analysis ...
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
The renal metastatic NSCLC with TKI-sensitive EGFR mutations revealed a good response to the third TKIs as osimertinib. Statement of Ethics The study was conducted in accordance with the Declaration ...
The phase 2b part of the REZILIENT1 trial (NCT04036682) trial evaluating zipalertinib monotherapy for the treatment of patients with non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion ...
SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth factor receptor (EGFR) mutations. The recommended dosing is weekly from Weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback